Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564511 | 0.99 | HRH3 (0.52) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3564760 | 0.94 | HRH3 (0.51) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3561359 | 0.92 | AURKA (0.49) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3571883 | 0.92 | AURKA (0.49) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3568697 | 0.91 | AURKA (0.51) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3571190 | 0.91 | CHEK1 (0.47) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3563690 | 0.91 | CHEK1 (0.59) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3566263 | 0.86 | AURKA (0.46) | HRH3AURKAAURKBCHEK1 | |
| SCHEMBL3567104 | 0.86 | CHEK1 (0.46) | TLR9TLR7HRH3HRH1AURKA | |
| SCHEMBL3570576 | 0.86 | AURKA (0.44) | HRH3HRH1AURKAAURKBCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | FLT3, ABL1, KIT | TLR9 1998/4885TLR7 837/4885HRH3 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.